Replimune Announces Executive and Board Changes

Ticker: REPL · Form: 8-K · Filed: 2025-03-07T00:00:00.000Z

Sentiment: neutral

Topics: executive-change, board-change, personnel

TL;DR

Replimune's CMO is out, a new interim CMO and two new directors are in. Board shakeup.

AI Summary

Replimune Group, Inc. announced on March 5, 2025, the departure of Dr. Robert L. Kirk as Chief Medical Officer and the appointment of Dr. Philip J. Kantoff as interim Chief Medical Officer. The company also reported the election of two new directors, Dr. Kantoff and Ms. Jennifer L. Choe, to its Board of Directors.

Why It Matters

Changes in key executive and board positions can signal shifts in company strategy or operational focus, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Executive and board changes can introduce uncertainty regarding leadership stability and strategic direction.

Key Players & Entities

FAQ

Who has been appointed as the interim Chief Medical Officer for Replimune Group, Inc.?

Dr. Philip J. Kantoff has been appointed as the interim Chief Medical Officer.

When did the reported events occur?

The earliest event reported was on March 5, 2025.

Who has departed from their role as Chief Medical Officer?

Dr. Robert L. Kirk has departed from his role as Chief Medical Officer.

How many new directors were elected to the Board?

Two new directors, Dr. Philip J. Kantoff and Ms. Jennifer L. Choe, were elected to the Board.

What is the principal executive office address for Replimune Group, Inc.?

The address is 500 Unicorn Park Drive, Suite 303, Woburn, MA 01801.

From the Filing

0001104659-25-021756.txt : 20250307 0001104659-25-021756.hdr.sgml : 20250307 20250307163030 ACCESSION NUMBER: 0001104659-25-021756 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250305 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250307 DATE AS OF CHANGE: 20250307 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Replimune Group, Inc. CENTRAL INDEX KEY: 0001737953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822082553 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38596 FILM NUMBER: 25720573 BUSINESS ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: (781) 222-9600 MAIL ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 8-K 1 tm258605d1_8k.htm FORM 8-K false 0001737953 0001737953 2025-03-05 2025-03-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM 8-K       CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  March 5, 2025       REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter)       Delaware   001-38596   82-2082553 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification Number)   500 Unicorn Park Drive Suite 303 Woburn , MA 01801 (Address of principal executive offices, including Zip Code)   Registrant’s telephone number, including area code: ( 781 ) 222-9600   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:     ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   REPL   The Nasdaq Stock Market LLC (Nasdaq Global Select Market)   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨             Item 1.01 Entry into a Material Definitive Agreement.   On March 5, 2025, Replimune Group, Inc. (the “Company”) entered into a registration rights agreement (the “Affiliate Registration Rights Agreement”) with 667, L.P. and Baker Brothers Life Sciences, L.P. (collectively, the “BBA Funds”), as more particularly described below under the heading “Affiliate Reg

View on Read The Filing